Esperion Therapeutics Inc.
ESPR
Market Cap$354.18M
Close$
$11.14
459.6% upside
Current Fair Value
459.6% upsideUndervalued by 459.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $354.18 Million |
|---|---|
| Enterprise Value | $812.88 Million |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $-2.03 |
| Beta | 1.84 |
| Outstanding Shares | 189,400,567 |
| Avg 30 Day Volume | 8,822,384 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -1.69 |
|---|---|
| PEG | -109.59 |
| Price to Sales | - |
| Price to Book Ratio | -0.66 |
| Enterprise Value to Revenue | 6.99 |
| Enterprise Value to EBIT | -5.23 |
| Enterprise Value to Net Income | -4 |
| Total Debt to Enterprise | 0.67 |
| Debt to Equity | -1.19 |
Revenue Sources
No data
ESG Score
No data
About Esperion Therapeutics Inc.
CEO: Timothy Mayleben